INOZYME PHARMA, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
INOZYME PHARMA, INC. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$28.04 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2025-05-14
- INOZYME PHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-03-31 was -$28.04M.
- INOZYME PHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-12-31 was -$27.07M.
- INOZYME PHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was -$24.57M.
- INOZYME PHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-06-30 was -$27.03M.
- INOZYME PHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$102.02M.
- INOZYME PHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$71.17M.
- INOZYME PHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$67.06M.
- INOZYME PHARMA, INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$56.62M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2025-03-31 | -$28.04M 10-Q · filed 2025-05-14 | -$55.11M derived: sum of 2 quarters · filed 2025-05-14 | -$79.68M derived: sum of 3 quarters · filed 2025-05-14 | -$106.72M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | -$27.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$51.64M derived: sum of 2 quarters · filed 2025-03-10 | -$78.68M derived: sum of 3 quarters · filed 2025-03-10 | -$102.02M 10-K · filed 2025-03-10 |
| 2024-09-30 | -$24.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$51.60M derived: sum of 2 quarters · filed 2024-11-05 | -$74.95M 10-Q · filed 2024-11-05 | -$96.49M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-06-30 | -$27.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$50.38M 10-Q · filed 2024-08-06 | -$71.92M derived: sum of 3 quarters · filed 2025-05-14 | -$88.56M derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-03-31 | -$23.35M 10-Q · filed 2025-05-14 | -$44.89M derived: sum of 2 quarters · filed 2025-05-14 | -$61.53M derived: sum of 3 quarters · filed 2025-05-14 | -$77.11M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$21.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$38.18M derived: sum of 2 quarters · filed 2025-03-10 | -$53.77M derived: sum of 3 quarters · filed 2025-03-10 | -$71.17M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$16.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$32.22M derived: sum of 2 quarters · filed 2024-11-05 | -$49.63M 10-Q · filed 2024-11-05 | -$68.17M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$15.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$32.99M 10-Q · filed 2024-08-06 | -$51.53M derived: sum of 3 quarters · filed 2024-08-06 | -$67.90M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$17.40M 10-Q · filed 2024-05-07 | -$35.95M derived: sum of 2 quarters · filed 2024-05-07 | -$52.32M derived: sum of 3 quarters · filed 2024-05-07 | -$67.58M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$18.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$34.92M derived: sum of 2 quarters · filed 2024-03-12 | -$50.18M derived: sum of 3 quarters · filed 2024-03-12 | -$67.06M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$16.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$31.63M derived: sum of 2 quarters · filed 2023-11-07 | -$48.52M 10-Q · filed 2023-11-07 | -$67.27M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$15.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$32.15M 10-Q · filed 2023-08-08 | -$50.90M derived: sum of 3 quarters · filed 2023-08-08 | -$65.18M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$16.88M 10-Q · filed 2023-05-09 | -$35.64M derived: sum of 2 quarters · filed 2023-05-09 | -$49.92M derived: sum of 3 quarters · filed 2023-05-09 | -$62.46M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$18.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$33.03M derived: sum of 2 quarters · filed 2023-03-22 | -$45.57M derived: sum of 3 quarters · filed 2023-03-22 | -$56.62M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$14.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$26.82M derived: sum of 2 quarters · filed 2022-11-10 | -$37.87M 10-Q · filed 2022-11-10 | -$48.99M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$12.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$23.59M 10-Q · filed 2022-08-15 | -$34.71M derived: sum of 3 quarters · filed 2022-08-15 | -$62.80M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$11.05M 10-Q · filed 2022-05-10 | -$22.17M derived: sum of 2 quarters · filed 2022-05-10 | -$50.26M derived: sum of 3 quarters · filed 2022-05-10 | -$59.74M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$11.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$39.21M derived: sum of 2 quarters · filed 2022-03-15 | -$48.69M derived: sum of 3 quarters · filed 2022-03-15 | -$56.42M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$28.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$37.57M derived: sum of 2 quarters · filed 2021-11-09 | -$45.31M 10-Q · filed 2021-11-09 | -$51.85M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | -$9.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$17.21M 10-Q · filed 2021-08-11 | -$23.75M derived: sum of 3 quarters · filed 2021-08-11 | -$27.79M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | -$7.74M 10-Q · filed 2021-05-12 | -$14.28M derived: sum of 2 quarters · filed 2021-05-12 | -$18.32M derived: sum of 3 quarters · filed 2021-05-12 | |
| 2019-12-31 | -$6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$10.58M derived: sum of 2 quarters · filed 2021-03-25 | -$19.72M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$4.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$13.18M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$9.14M 10-Q · filed 2020-09-03 |